Clene Inc. (NASDAQ:CLNNW) Short Interest Down 18.0% in September

Clene Inc. (NASDAQ:CLNNW) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 5,000 shares, a decrease of 18.0% from the September 15th total of 6,100 shares. Based on an average daily volume of 7,500 shares, the short-interest ratio is currently 0.7 days.

Clene Stock Performance

CLNNW traded up $0.02 during midday trading on Friday, reaching $0.05. The company had a trading volume of 5,791 shares, compared to its average volume of 10,917. The business has a 50-day moving average of $0.04 and a two-hundred day moving average of $0.04. Clene has a 1 year low of $0.02 and a 1 year high of $0.09.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.